Date:6/10/2009

Follicle Stimulating Hormone." June 30 4th Annual Biopharm Asia Conference Singapore Duu-Gong Wu, PhD, Executive Director, PharmaNet Consulting, will make a presentation entitled "Overview of Follow-on Biologics Regulatory and Scientific Issues in US." He will also lead a post conference workshop on July 1 on the topic of the FDA's approval process for biologics and biological products. 49th Annual Meeting of the Teratology Society Rio Grande, Puerto Rico Bengt Danielsson, MD, PhD, Vice President, PharmaNet Consulting, will present "Exaggerated Pharmacology Versus True Toxicity." Dr. Danielsson's presentation is part of the International Life Sciences Institute and the Health and Environmental Sciences Institute's (ILSI/HESI) symposium on Maternal Toxicity and its Impact on Study Design and Data Interpretation.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,400 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com

'/>"/>

SOURCE PharmaNet Development Group, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
2. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
3. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
4. PharmaNet Development Group Agrees to be Acquired by JLL Partners
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Plexus Awarded Development Contract With QIAGEN
7. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
8. Microbia, Inc. Names Alex Chu as Vice President of Process Development
9. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
10. Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development
11. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments